2nd Taiwan COVID vaccine maker to apply for EUA on Phase 2 data

Taiwanese vaccine maker United Biomedical Inc. (UBI) Asia announced Sunday that it will seek emergency use authorization (EUA) in Taiwan for its COVID-19 vaccine candidate before the end of June after unveiling the interim results of its Phase 2 clinical trials.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)